Healthcare Moves: A Monthly Summary of Hires and Layoffs
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
After getting FDA clearance for video game therapeutic, Akili faces next level: insurance coverage
Akili Interactive, a digital health company that got FDA clearance last year for its video game as treatment for ADHD, recently brought in $160 million in funding. It plans to use the funds to ramp up coverage of its flagship treatment and to develop digital treatments for other cognitive conditions.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Akili tests if therapeutic game could be used to treat Covid ‘brain fog’
Akili Interactive received FDA clearance last year for its game-based digital therapeutic to be used as a treatment for ADHD. Now, the company is testing it to see if it could help people experiencing cognitive dysfunction after Covid-19.
Akili’s long journey to build the first video game as a treatment
After years of work, Akili received FDA clearance for its video game to be used as a treatment for ADHD. CEO Eddie Martucci shared what went into that process and what’s next.
In a first, FDA clears video game for kids with ADHD
Digital health company Akili Interactive received FDA de novo clearance for its digital therapeutic, a video game intended to improve attention among kids with ADHD.
Digital therapeutics make strides during pandemic, but still face adoption hurdles
Lightened regulations and cancelled appointments have led to an uptick in the number of patients using digital therapeutics. But companies still face many of the same obstacles as before, including securing coverage and reimbursement from insurers.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Digital therapeutics startup Akili Interactive inks deal with Japanese pharma company
In exchange for ceding rights to develop, sell and market Akili's two lead products in Japan and Taiwan to Shionogi, Akili will receive $20 million upfront and up to $105 million in additional payments dependent on reaching certain development and commercial milestones.